Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11601226 | 0.83 | AR (0.54) | ARNR1H3NR1H2TSHRHSD17B10 | |
| SCHEMBL7937259 | 0.82 | ESR2 (0.50) | ARNR1H3NR1H2TSHRHSD17B10 | |
| SCHEMBL29430111 | 0.81 | PDE2A (0.53) | TSHRHSD17B10MEN1KMT2ACA1 | |
| SCHEMBL225921 | 0.81 | PDE2A (0.53) | TSHRHSD17B10MEN1KMT2ACA1 | |
| SCHEMBL5388124 | 0.81 | TSHR (0.50) | ARNR1H3NR1H2TSHRHSD17B10 | |
| SCHEMBL17287088 | 0.81 | ALOX15 (0.52) | ARNR1H3NR1H2TSHRHSD17B10 | |
| Potassium SCHEMBL30520491 | 0.79 | PDE2A (0.52) | TSHRHSD17B10MEN1KMT2ACA1 | |
| Water SCHEMBL29058831 | 0.79 | PDE2A (0.52) | TSHRHSD17B10MEN1KMT2ACA1 | |
| SCHEMBL27487833 | 0.79 | PDE2A (0.52) | TSHRHSD17B10MEN1KMT2ACA1 | |
| SCHEMBL28426979 | 0.79 | PDE2A (0.52) | TSHRHSD17B10MEN1KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | AR 146/4885NR1H3 2/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.